Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide

Many patients with multiple sclerosis (MS) receive disease-modifying therapies (DMTs), such as teriflunomide, to reduce disease activity and slow progression. DMTs mediate their efficacy by modulating or suppressing the immune system, which might affect a patient's response to vaccination. As v...

Descripción completa

Detalles Bibliográficos
Autores principales: Tornatore, Carlo, Wiendl, Heinz, Lublin, Alex L., Geertsen, Svend S., Chavin, Jeffrey, Truffinet, Philippe, Bar-Or, Amit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918991/
https://www.ncbi.nlm.nih.gov/pubmed/35295832
http://dx.doi.org/10.3389/fneur.2022.828616

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918991/
https://www.ncbi.nlm.nih.gov/pubmed/35295832
http://dx.doi.org/10.3389/fneur.2022.828616

Ejemplares similares